Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

Blood (2024) 144 (22): 2319–2326.

https://doi.org/10.1182/blood.2024024300

Published: 2024

Includes: Supplemental data

Journal Articles

T-ALL and T-LBL: a notch apart

Rachael Pocock, Marc R. Mansour

Blood (2024) 144 (13): 1356–1357.

https://doi.org/10.1182/blood.2024026122

Published: 2024

Journal Articles

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Blood (2022) 140 (Supplement 1): 1009–1010.

https://doi.org/10.1182/blood-2022-162930

Published: 2022

Journal Articles

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Blood (2022) 140 (1): 25–37.

https://doi.org/10.1182/blood.2021013648

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Selina J Chavda, MBBS, BSc, MRCP, Rachael Pocock, MBBS, BSc, MRCP, Simon Cheesman, BPharm, Emma Dowling, Puneet Verma, MRPharmS, Malcolm Walker, MBBS, MBChB, MD FRCP, Charalampia Kyriakou, MD PhD, Ashutosh D. Wechalekar, Neil K Rabin, MD, Kwee Yong, MD PhD, Rakesh Popat, MBBS, BSc, MRCP, FRCPath, PhD

Blood (2018) 132 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2018-99-113832

Published: 2018

NARROW

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

T-ALL and T-LBL: a notch apart

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia

T-ALL and T-LBL: a notch apart

IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Real World Analysis of the Incidence and Impact of Hypertension and Cardiac Toxicity Associated with Carfilzomib for Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only